Table 2.
Included studies for the survival of endometrial cancer and HIF-1α expression.
| Author | Reference | Time | Country | Ethnicity | Tumor stage | Detected sample | Num. | Follow-up median | Method | Survival analysis | Source of HR | HR | LL | UL | P | Cut-off | 95%CI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abouhashem | (29) | 2016 | Egypt | Mixed | IHC | ECT | 50 | 12 | OS | Curve | 3.36 | 0.84 | 6.02 | 0.097 | 10% | 0.84-6.02 | |
| Berg | (30) | 2016 | Norway | Caucasians | IHC | ECT | 86 | 30 | OS | HR | 2.17 | 1.37 | 3.49 | 0.004 | NR | 1.37-3.49 | |
| Seeber | (31) | 2010 | Netherlands | Caucasians | IHC | ECT | 54 | 95 | OS | Curve | 2.53 | 0.78 | 4.28 | 0.235 | NR | 0.78-4.28 | |
| Sivridis | (32) | 2002 | UK | Caucasians | IHC | ECT | 81 | 75 | OS | Curve | 1.86 | 1.04 | 3.64 | 0.03 | NR | 1.04-3.64 | |
| Aybatli | (33) | 2012 | Turkey | Caucasians | IHC | ECT | 76 | 56 | OS | Curve | 1.85 | 0.83 | 3.61 | 0.222 | 0% | 0.83-3.61 | |
| Soo | (34) | 2017 | Korea | Asians | IHC | ECT | 140 | 104 | OS | HR | 3.79 | 2.18 | 6.35 | 0.001 | 0% | 2.18-6.35 |
ECT, endometrial carcinoma tissue; IHC, immunohistochemistry; OS, overall survival; HR, hazard ratio; NR, not reported.